Malta - English - Medicines Authority

1 a pharma gmbh - nevirapine 200 mg - tablet

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use

European Union - English - EMA (European Medicines Agency)

teva b.v.  - nevirapine - hiv infections - antivirals for systemic use - nevirapine teva is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv 1 infected adults, adolescents, and children of any age.most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (nrtis). the choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - nevirapine - hiv infections - antivirals for systemic use - tablets and oral suspensionviramune is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1-infected adults, adolescents, and children of any age.most of the experience with viramune is in combination with nucleoside reverse-transcriptase inhibitors (nrtis). the choice of a subsequent therapy after viramune should be based on clinical experience and resistance testing.50- and 100-mg prolonged-release tabletsviramune is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1-infected adolescents and children three years and above and able to swallow tablets.prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.most of the experience with viramune is in combination with nucleoside reverse-transcriptase inhibitors (nrtis). the choice of a subsequent therapy after viramune should be based on clinical experience and resistance testing.400-mg prolonged-release tabletsviramune is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1-infected adults, adolescents and children three years and above and able to swallow tablets.prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. other nevirapine formulations, such as immediate-release tablets or oral suspension should be used.most of the experience with viramune is in combination with nucleoside reverse-transcriptase inhibitors (nrtis). the choice of a subsequent therapy after viramune should be based on clinical experience and resistance testing.

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - nevirapine - tablet - 200mg - nevirapine 200mg - nonnucleoside reverse transcriptase inhibitors

Canada - English - Health Canada

auro pharma inc - nevirapine - tablet - 200mg - nevirapine 200mg - nonnucleoside reverse transcriptase inhibitors

Canada - English - Health Canada

teva canada limited - nevirapine - tablet - 200mg - nevirapine 200mg - nonnucleoside reverse transcriptase inhibitors

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - nevirapine - tablet (extended-release) - 400mg - nevirapine 400mg - nonnucleoside reverse transcriptase inhibitors

Canada - English - Health Canada

mylan pharmaceuticals ulc - nevirapine - tablet - 200mg - nevirapine 200mg - nonnucleoside reverse transcriptase inhibitors

Canada - English - Health Canada

apotex inc - nevirapine - tablet - 200mg - nevirapine 200mg - nonnucleoside reverse transcriptase inhibitors